Big pharma still continues to look upon antibiotic resistance as somebody else’s problem, the World Health Organization has warned, in a dismal update outlining the lack of private investme
Eli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as it seeks to build its R&D pipeline, its chief financial officer has said.
AstraZeneca has axed a large late-stage trial for its heart disease drug Epanova in patients with mixed dyslipidemia (MDL), and expects to write off at least $100 million from its profits i
